Project Grant R01HL182864
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $638K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $713,515 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate the neural mechanisms linking meal timing, circadian rhythms, and blood pressure control in diet-induced obesity. The project, titled "Food Intake Timing on Circadian Control of Blood Pressure in Diet-Induced Obesity," seeks to elucidate how the suprachiasmatic nucleus and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 15, 2026, for Project Grant R03HL185264 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the mechanisms of CAV1.2 dysregulation in hypertension. CAV1.2, a voltage-activated calcium channel essential for blood pressure regulation, is abnormally active in spontaneously hypertensive rats and contributes to excessive...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Louisiana State University Health Sciences Center New Orleans $1,008,719 on April 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to screen and validate microRNA targets for neurogenic hypertension. The work addresses treatment-resistant neurogenic hypertension, which accounts for a substantial share of resistant hypertension cases and stems from increased sympathetic outflow from the...
- The National Heart, Lung, and Blood Institute awarded the University of Missouri System $840,770 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the interplay of central and peripheral vascular effects of insulin in obesity. The research focuses on skeletal muscle blood flow impairment and glucose uptake dysregulation in individuals with obesity and insulin resistance. The project examines how central (brain) insulin sensitivity drives sympathetic...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $128,589 on September 27, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the contribution of JNK signaling to exercise pressor reflex dysfunction in primary hypertension. The research tests the hypothesis that enhanced JNK signaling in dorsal root ganglia of hypertensive mice occurs through increased peripheral tumor necrosis factor-alpha, resulting in...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $622,619 on August 15, 2026, to conduct research targeting hypothalamic astrocytes in obesity-associated hypertension under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL187653). The project investigates how chronic overnutrition alters brain circuits through elevated adipose hormone leptin, causing increased sympathetic outflow and blood pressure elevation. The research focuses on...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $865,711 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate beta-2 adrenergic receptor polymorphic variants as an endotype of salt-sensitive hypertension. The recipient will conduct translational research in humans and mice carrying either the risk (ARG16ARG/GLN27GLN) or non-risk (GLY16GLY/GLU27GLU) beta-2 adrenergic receptor diplotypes to distinguish between...
- The National Heart, Lung, and Blood Institute awarded The University of Kentucky Research Foundation $724,259 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of asprosin-PTPRD signaling in neural regulation of blood pressure. The project elucidates how asprosin, an adipokine pathologically elevated in metabolic syndrome, hypertension, and obesity, engages protein tyrosine phosphatase type delta (PTPRD) receptors to modulate blood...
- The National Heart, Lung, and Blood Institute awarded $2.609 million to Vanderbilt University Medical Center on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathophysiological mechanisms of mitochondrial cyclophilin D acetylation in vascular dysfunction and hypertension through September 29, 2028. The project will define cell-specific pathogenic mechanisms of endothelial and smooth muscle cyclophilin D acetylation in hypertension and vascular...